Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

620 ARTÍCULOS , VIENDO DEL 436 AL 450

A review of the mechanisms underlying selected comorbidities in Alzheimer's disease

Maciejewska K, Czarnecka K, Szymański P.

Pharmacol Rep. 2021 Dec;73(6):1565-1581. doi: 10.1007/s43440-021-00293-5. Epub 2021 Jun 13.

The preventive efficacy of vitamin B supplements on the cognitive decline of elderly adults: a systematic review and meta-analysis

Li S, Guo Y, Men J, Fu H, Xu T.

BMC Geriatr. 2021 Jun 16;21(1):367. doi: 10.1186/s12877-021-02253-3.

Role of Withaferin A and Its Derivatives in the Management of Alzheimer's Disease: Recent Trends and Future Perspectives

Das R, Rauf A, Akhter S, Islam MN, Emran TB, Mitra S, Khan IN, Mubarak MS.

Molecules. 2021 Jun 17;26(12):3696. doi: 10.3390/molecules26123696.

The effect and underlying mechanisms of garlic extract against cognitive impairment and Alzheimer's disease: A systematic review and meta-analysis of experimental animal studies

Luo JF, Dong Y, Chen JY, Lu JH.

J Ethnopharmacol. 2021 Nov 15;280:114423. doi: 10.1016/j.jep.2021.114423. Epub 2021 Jul 14.

Editorial: Targets for Disease-Modifying Therapies in Alzheimer's Disease, Including Amyloid β and Tau Protein

Parums DV.

Med Sci Monit. 2021 Jul 26;27:e934077. doi: 10.12659/MSM.934077.

Fatty acids and beyond: Age and Alzheimer's disease related changes in lipids reveal the neuro-nutraceutical potential of lipids in cognition

Ooi KM, Vacy K, Boon WC.

Neurochem Int. 2021 Oct;149:105143. doi: 10.1016/j.neuint.2021.105143. Epub 2021 Jul 23.

Aducanumab: First Approval

Dhillon S.

Drugs. 2021 Aug;81(12):1437-1443. doi: 10.1007/s40265-021-01569-z.

Improvement of cognitive performance by a nutraceutical formulation: Underlying mechanisms revealed by laboratory studies

Shea TB.

Free Radic Biol Med. 2021 Oct;174:281-304. doi: 10.1016/j.freeradbiomed.2021.07.039. Epub 2021 Aug 2.

Brain Glucose Transporters: Role in Pathogenesis and Potential Targets for the Treatment of Alzheimer's Disease

Szablewski L.

Int J Mol Sci. 2021 Jul 29;22(15):8142. doi: 10.3390/ijms22158142.

Five-year outcomes after IVIG for mild cognitive impairment due to alzheimer disease

Kile S, Au W, Parise C, Rose K, Donnel T, Hankins A, Au Y, Chan M, Ghassemi A.

BMC Neurosci. 2021 Aug 6;22(1):49. doi: 10.1186/s12868-021-00651-2.

Leukotriene receptor antagonist use and cognitive decline in normal cognition, mild cognitive impairment, and Alzheimer's dementia

Xiong LY, Ouk M, Wu CY, Rabin JS, Lanctôt KL, Herrmann N, Black SE, Edwards JD, Swardfager W.

Alzheimers Res Ther. 2021 Sep 3;13(1):147. doi: 10.1186/s13195-021-00892-7.

A meta-analysis of randomised controlled trials of physical activity in people with Alzheimer's disease and mild cognitive impairment with a comparison to donepezil

Pisani S, Mueller C, Huntley J, Aarsland D, Kempton MJ.

Int J Geriatr Psychiatry. 2021 Oct;36(10):1471-1487. doi: 10.1002/gps.5581. Epub 2021 May 25.

Current Alzheimer disease research highlights: evidence for novel risk factors

Brenowitz WD, Xiang Y, McEvoy CT, Yang C, Yaffe K, Le WD, Leng Y.

Chin Med J (Engl). 2021 Sep 9;134(18):2150-2159. doi: 10.1097/CM9.0000000000001706.

The role of orexin in Alzheimer disease: From sleep-wake disturbance to therapeutic target

Gao F, Liu T, Tuo M, Chi S.

Neurosci Lett. 2021 Nov 20;765:136247. doi: 10.1016/j.neulet.2021.136247. Epub 2021 Sep 14.

Effects of Supplementation with Folic Acid and Its Combinations with Other Nutrients on Cognitive Impairment and Alzheimer's Disease: A Narrative Review

Puga AM, Ruperto M, Samaniego-Vaesken ML, Montero-Bravo A, Partearroyo T, Varela-Moreiras G.

Nutrients. 2021 Aug 26;13(9):2966. doi: 10.3390/nu13092966.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias